The Silicon Review - Best Business Review Magazine 50 Most Trustworthy Companies 2019 | Page 81

excellent when it comes to disrupting
traditional cancer treatments.
More importantly, we have aligned
ourselves with leaders within immuno-
oncology and they have come alongside
us in carrying our message to the
community.
What do you feel are the
reasons behind your company’s
reputation?
The foundation of our reputation:
People see we have leaders within the
medical and scientific communities that
are aligned with business leaders who
do business ethically.
In addition, our cutting edge scientific
advisory board has had a significant role
in helping us to frame our roadmap.
Where do you see your company
a couple of years from now?
Our solution has the potential to have
a global footprint providing low-cost
cancer treatment solutions for many
patients.
SR
Allan Camaisa: A Proven Leader
Allan Camaisa a serial entrepreneur, investor,
and technologist, with proven leadership skills in
bootstrapping start-ups. He has had three successful
exits, which were sold to publicly traded Fortune
1000 companies. Mr. Camaisa has always created
tremendous return for his shareholders. He has
proven operational experience in recruiting the right
team, creating a culture of trust, and collaboration.
Since taking over as Chairman and CEO, of Calidi
Biotherapeutics, he signed an agreement with National
Institute of Health (NIH), recruited top immunologists
to the Scientific Advisory Board, and entered license
negotiations with large pharmaceutical organizations.
Prior to Calidi, Mr. Camaisa was the CEO and Chairman
of Parallel6, Inc., a creator of a digital mobile software
platform which engaged clinical trial participants and
powered the enrollment, management, and retention
of those participants on behalf of pharmaceutical
organizations. Parallel6 was sold to PRA Health
Sciences in 2017. Their clients included Sanofi, STSI/
Genentech, Johnson & Johnson/Janssen, Abbott/
Abbvie, PPD, PRA Health, Pfizer, Roche, and the NIH,
among others.
In 2005, Mr. Camaisa founded Anakam, Inc., a
software security company, focused on healthcare,
which safeguarded digital medical records through
a platform which delivered government level
multifactor authentication and security. Anakam sold
a global license to the Veterans Administration (VA)
to secure access to the VA’s primary patient portal
called My HealtheVet. Other notable Anakam clients
included the Center for
Medicare and Medicaid,
the Department of
Homeland Security and
several medical device
companies including
Boston Scientific and
EntraHealth. Anakam
was recognized by INC
Allan Camaisa, CEO
500 as one of the fastest
growing companies in
the U.S. and was acquired by Equifax in 2010.
Prior to Anakam, Mr. Camaisa founded High
Technology Solutions (HTS), a software systems
integrator which he grew from just two colleagues to
over 500 employees and $50 million in revenues. HTS
was recognized as an INC 500 company three years
in a row and was sold to Wireless Facilities, Inc. (now
Kratos Defense) in 2004.
Before entering the business, Mr. Camaisa served eight
years as a surface warfare officer in the United States
Navy. He currently owns seven U.S. patents and has
received many personal awards including the Deloitte
FAST 50, the Governor’s Small Business of the Year
Award and the Ernst and Young Regional Entrepreneur
of the Year. He also received awards from the San Diego
Asian Business Association, Tech America, and the U.S.
Small Business Association, which honored him as
Small Business Person of the Year.
Mr. Camaisa is a graduate of both the United
States Naval Academy and the prestigious Owners
Management Program at Harvard Business School.
81